Page last updated: 2024-12-07

2-nitrophenylacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

(2-nitrophenyl)acetic acid : A member of the class of phenylacetic acids that is phenylacetic acid in which the phenyl grup is substituted at the ortho- position by a nitro group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID77337
CHEBI ID187870
SCHEMBL ID124031
MeSH IDM0306952

Synonyms (53)

Synonym
2-nitrobenzeneacetic acid
brn 1959243
ccris 2336
nsc 16624
einecs 223-128-0
ai3-31297
BB 0219319
(2-nitro-phenyl)-acetic acid
unii-05tn0suy38
05tn0suy38 ,
2-nitrophenylacetic acid ,
2-(o-nitrophenyl)acetic acid
nsc-16624
o-nitrophenylacetic acid
3740-52-1
(2-nitrophenyl)acetic acid
nsc16624
acetic acid, (o-nitrophenyl)-
(ortho-nitrophenyl)acetic acid
benzeneacetic acid, 2-nitro-
2-nitrophenylacetic acid, 98%
OPREA1_132121
STK411127
AKOS000104760
N0353
CHEBI:187870
ortho-nitrophenylacetic acid
2-(2-nitrophenyl)acetic acid
A24278
2-nitro phenylacetic acid
BBL011770
FT-0613208
PS-4967
AM20060243
o-nitrophenyl acetic acid
orthonitrophenylacetic acid
2-nitrophenyl acetic acid
SCHEMBL124031
DTXSID0063157
cambridge id 5102607
W-106540
STR03477
CS-W019512
nitrophenylacetic acid, o-
mfcd00007190
F0051-0001
SY002275
2-(2-nitrophenyl)aceticacid
Q27236144
P16508
PB47632
EN300-18353
Z57270339
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
phenylacetic acidsAny monocarboxylic acid that is phenylacetic acid or its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's3 (37.50)29.6817
2010's3 (37.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.50 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index19.78 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]